Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Print: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i1.40
pages 31-50

Therapeutic Targeting of the Epidermal Growth Factor Receptor in Human Cancer

Nathalie S. Dhomen
Ludwig Institute for Cancer Research, Melbourne, Australia
John Mariadason
Ludwig Institute for Cancer Research, Melbourne, Australia
Niall Tebbutt
Ludwig Institute for Cancer Research, Melbourne, Australia
Andrew M. Scott
Ludwig Institute for Cancer Research, Melbourne, Australia


The epidermal growth factor receptor (EGFR; also referred to as HER1 or ERBB1), is a member of the type 1 receptor tyrosine kinase family known as the ERBB family. Comprising 4 members−ERBB1, ERBB2 (also known as HER2), ERBB3 (HER3), and ERBB4 (HER4)−these receptors play a principal role in allowing cells to integrate and respond correctly to diverse external stimuli, ranging from soluble endocrine and paracrine factors to signaling molecules on neighboring cells. The cell must interpret these extracellular signals to produce an appropriate developmental or proliferative response, and aberrant activation of the kinase activity of these receptors, particularly EGFR and ERBB2, is important in the development and progression of human cancer. Given its roles in signal transduction and development of the malignant phenotype, EGFR has emerged as a critical target for therapeutic development against various forms of cancer. This review focuses on the current therapeutic approaches directed against EGFR, the emerging challenges of EGFR therapy resistance, and how our increasing knowledge of EGFR biology is driving more targeted or alternative approaches to cancer therapies.

Articles with similar content:

Targeting the Human Kinome for Cancer Therapy: Current Perspectives
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Luxi Zhang , Roger J. Daly
Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 1
Carlos L. Arteaga, Brent N. Rexer
TAM Receptors in Leukemia: Expression, Signaling, and Therapeutic Implications
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 1-2
Justine Migdall-Wilson, Douglas K. Graham, Kristen Eisenman, Luis Brandao
Natural Products as Inhibitors of Epidermal Growth Factor Receptor
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth
Tuning the Rheostat of the Myelopoietic System via Fas and TRAIL
Critical Reviews™ in Immunology, Vol.23, 2003, issue 4
Inge Tinhofer, Gabriele Anether, Richard Greil, Karin Johrer